ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

{"_buckets": {"deposit": "f64153cd-7c84-4f60-8763-8c64333ce0f3"}, "_deposit": {"id": "27083", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "27083"}, "status": "published"}, "_oai": {"id": "oai:nagoya.repo.nii.ac.jp:00027083", "sets": ["501"]}, "author_link": ["88794", "88795", "88796", "88797", "88798", "88799", "88800", "88801", "88802", "88803"], "item_10_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2018-11", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "11", "bibliographicPageEnd": "1030", "bibliographicPageStart": "1023", "bibliographicVolumeNumber": "23", "bibliographic_titles": [{"bibliographic_title": "Nephrology", "bibliographic_titleLang": "en"}]}]}, "item_10_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Aim: We aimed to evaluate the anti‐albuminuric effects of topiroxostat in Japanese hyperuricaemic patients with diabetic nephropathy. Methods: In this 24‐week, multicentre, open‐label, randomized (1 : 1) trial, we assigned hyperuricaemic patients with diabetic nephropathy (estimated glomerular filtration rate ≥ 20 mL/min per 1.73m2) and overt proteinuria (0.3 ≤ urine protein to creatinine ratio (UPCR) \u003c3.5 g/g Cr) to either high dose (160 mg daily) or low dose (40 mg daily) topiroxostat. The primary endpoint was the change in albuminuria indicated by urine albumin‐to‐creatinine ratio (UACR) from the baseline at the final time point. Results: A total of 80 patients underwent randomization. The changes in UACR after 24 weeks of treatment (or at the final time point if patients failed to reach 24 weeks) relative to the baseline were −122 mg/gCr (95% CI: −5.1 to −240.1, P = 0.041) in patients treated with high dose, while treatment with low dose topiroxostat could not show significant reduction (P = 0.067). In the linear mixed model including baseline albuminuria, eGFR, age, and sex as covariates, the decreases in UACR were still significant from baseline to 12 weeks by 228.7 ± 83.2 mg/gCr (P = 0.0075) in the high dose group. The adverse‐event profile during this study was not different between the groups. Conclusion: Topiroxostat 160 mg daily reduced albuminuria in patients with diabetic nephropathy. (Funded by Sanwa Kagaku Kenkyusho; Trial registration, UMIN000015403). ", "subitem_description_language": "en", "subitem_description_type": "Abstract"}]}, "item_10_description_5": {"attribute_name": "内容記述", "attribute_value_mlt": [{"subitem_description": "ファイル公開:2019-11-01", "subitem_description_language": "ja", "subitem_description_type": "Other"}]}, "item_10_publisher_32": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Wiley", "subitem_publisher_language": "en"}]}, "item_10_relation_11": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://doi.org/10.1111/nep.13177", "subitem_relation_type_select": "DOI"}}]}, "item_10_rights_12": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "This is the peer reviewed version of the following article: [Mizukoshi, T. , Kato, S. , Ando, M. , Sobajima, H. , Ohashi, N. , Naruse, T. , Saka, Y. , Shimizu, H. , Nagata, T. and Maruyama, S. (2018), Renoprotective effects of topiroxostat for Hyperuricaemic patients with overt diabetic nephropathy study (ETUDE study): A prospective, randomized, multicentre clinical trial. Nephrology, 23: 1023-1030. doi:10.1111/nep.13177], which has been published in final form at [https://doi.org/10.1111/nep.13177]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.", "subitem_rights_language": "en"}]}, "item_10_select_15": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_select_item": "author"}]}, "item_10_source_id_61": {"attribute_name": "ISSN(print)", "attribute_value_mlt": [{"subitem_source_identifier": "1320-5358", "subitem_source_identifier_type": "PISSN"}]}, "item_1615787544753": {"attribute_name": "出版タイプ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_ab4af688f83e57aa", "subitem_version_type": "AM"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "open access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_abf2"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Mizukoshi, Toshihiro", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "88794", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kato, Sawako", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "88795", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ando, Masahiko", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "88796", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Sobajima, Hiroshi", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "88797", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ohashi, Norimi", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "88798", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Naruse, Tomohiko", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "88799", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Saka, Yosuke", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "88800", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Shimizu, Hideaki", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "88801", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nagata, Takanobu", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "88802", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Maruyama, Shoichi", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "88803", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2019-11-01"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "1_repositoryETUDE_Nephrology.pdf", "filesize": [{"value": "1.7 MB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_note", "mimetype": "application/pdf", "size": 1700000.0, "url": {"label": "1_repositoryETUDE_Nephrology", "objectType": "fulltext", "url": "https://nagoya.repo.nii.ac.jp/record/27083/files/1_repositoryETUDE_Nephrology.pdf"}, "version_id": "fee2d56d-0b17-49a0-aef7-de207c641be4"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "albuminuria", "subitem_subject_scheme": "Other"}, {"subitem_subject": "diabetic nephropathy", "subitem_subject_scheme": "Other"}, {"subitem_subject": "randomized study", "subitem_subject_scheme": "Other"}, {"subitem_subject": "topiroxostat", "subitem_subject_scheme": "Other"}, {"subitem_subject": "xanthine oxidoreductase inhibitor", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Renoprotective effects of topiroxostat for Hyperuricaemic patients with overt diabetic nephropathy study (ETUDE study): A prospective, randomized, multicentre clinical trial", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Renoprotective effects of topiroxostat for Hyperuricaemic patients with overt diabetic nephropathy study (ETUDE study): A prospective, randomized, multicentre clinical trial", "subitem_title_language": "en"}]}, "item_type_id": "10", "owner": "1", "path": ["501"], "permalink_uri": "http://hdl.handle.net/2237/00029282", "pubdate": {"attribute_name": "PubDate", "attribute_value": "2019-02-13"}, "publish_date": "2019-02-13", "publish_status": "0", "recid": "27083", "relation": {}, "relation_version_is_last": true, "title": ["Renoprotective effects of topiroxostat for Hyperuricaemic patients with overt diabetic nephropathy study (ETUDE study): A prospective, randomized, multicentre clinical trial"], "weko_shared_id": -1}
  1. C100 医学部/医学系研究科
  2. C100a 雑誌掲載論文
  3. 学術雑誌

Renoprotective effects of topiroxostat for Hyperuricaemic patients with overt diabetic nephropathy study (ETUDE study): A prospective, randomized, multicentre clinical trial

http://hdl.handle.net/2237/00029282
http://hdl.handle.net/2237/00029282
ba481603-ad8e-4320-b2fb-ced549ecdd4a
名前 / ファイル ライセンス アクション
1_repositoryETUDE_Nephrology.pdf 1_repositoryETUDE_Nephrology (1.7 MB)
Item type 学術雑誌論文 / Journal Article(1)
公開日 2019-02-13
タイトル
タイトル Renoprotective effects of topiroxostat for Hyperuricaemic patients with overt diabetic nephropathy study (ETUDE study): A prospective, randomized, multicentre clinical trial
言語 en
著者 Mizukoshi, Toshihiro

× Mizukoshi, Toshihiro

WEKO 88794

en Mizukoshi, Toshihiro

Search repository
Kato, Sawako

× Kato, Sawako

WEKO 88795

en Kato, Sawako

Search repository
Ando, Masahiko

× Ando, Masahiko

WEKO 88796

en Ando, Masahiko

Search repository
Sobajima, Hiroshi

× Sobajima, Hiroshi

WEKO 88797

en Sobajima, Hiroshi

Search repository
Ohashi, Norimi

× Ohashi, Norimi

WEKO 88798

en Ohashi, Norimi

Search repository
Naruse, Tomohiko

× Naruse, Tomohiko

WEKO 88799

en Naruse, Tomohiko

Search repository
Saka, Yosuke

× Saka, Yosuke

WEKO 88800

en Saka, Yosuke

Search repository
Shimizu, Hideaki

× Shimizu, Hideaki

WEKO 88801

en Shimizu, Hideaki

Search repository
Nagata, Takanobu

× Nagata, Takanobu

WEKO 88802

en Nagata, Takanobu

Search repository
Maruyama, Shoichi

× Maruyama, Shoichi

WEKO 88803

en Maruyama, Shoichi

Search repository
アクセス権
アクセス権 open access
アクセス権URI http://purl.org/coar/access_right/c_abf2
権利
言語 en
権利情報 This is the peer reviewed version of the following article: [Mizukoshi, T. , Kato, S. , Ando, M. , Sobajima, H. , Ohashi, N. , Naruse, T. , Saka, Y. , Shimizu, H. , Nagata, T. and Maruyama, S. (2018), Renoprotective effects of topiroxostat for Hyperuricaemic patients with overt diabetic nephropathy study (ETUDE study): A prospective, randomized, multicentre clinical trial. Nephrology, 23: 1023-1030. doi:10.1111/nep.13177], which has been published in final form at [https://doi.org/10.1111/nep.13177]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.
キーワード
主題Scheme Other
主題 albuminuria
キーワード
主題Scheme Other
主題 diabetic nephropathy
キーワード
主題Scheme Other
主題 randomized study
キーワード
主題Scheme Other
主題 topiroxostat
キーワード
主題Scheme Other
主題 xanthine oxidoreductase inhibitor
抄録
内容記述 Aim: We aimed to evaluate the anti‐albuminuric effects of topiroxostat in Japanese hyperuricaemic patients with diabetic nephropathy. Methods: In this 24‐week, multicentre, open‐label, randomized (1 : 1) trial, we assigned hyperuricaemic patients with diabetic nephropathy (estimated glomerular filtration rate ≥ 20 mL/min per 1.73m2) and overt proteinuria (0.3 ≤ urine protein to creatinine ratio (UPCR) <3.5 g/g Cr) to either high dose (160 mg daily) or low dose (40 mg daily) topiroxostat. The primary endpoint was the change in albuminuria indicated by urine albumin‐to‐creatinine ratio (UACR) from the baseline at the final time point. Results: A total of 80 patients underwent randomization. The changes in UACR after 24 weeks of treatment (or at the final time point if patients failed to reach 24 weeks) relative to the baseline were −122 mg/gCr (95% CI: −5.1 to −240.1, P = 0.041) in patients treated with high dose, while treatment with low dose topiroxostat could not show significant reduction (P = 0.067). In the linear mixed model including baseline albuminuria, eGFR, age, and sex as covariates, the decreases in UACR were still significant from baseline to 12 weeks by 228.7 ± 83.2 mg/gCr (P = 0.0075) in the high dose group. The adverse‐event profile during this study was not different between the groups. Conclusion: Topiroxostat 160 mg daily reduced albuminuria in patients with diabetic nephropathy. (Funded by Sanwa Kagaku Kenkyusho; Trial registration, UMIN000015403).
言語 en
内容記述タイプ Abstract
内容記述
内容記述 ファイル公開:2019-11-01
言語 ja
内容記述タイプ Other
出版者
言語 en
出版者 Wiley
言語
言語 eng
資源タイプ
資源タイプresource http://purl.org/coar/resource_type/c_6501
タイプ journal article
出版タイプ
出版タイプ AM
出版タイプResource http://purl.org/coar/version/c_ab4af688f83e57aa
DOI
関連タイプ isVersionOf
識別子タイプ DOI
関連識別子 https://doi.org/10.1111/nep.13177
ISSN(print)
収録物識別子タイプ PISSN
収録物識別子 1320-5358
書誌情報 en : Nephrology

巻 23, 号 11, p. 1023-1030, 発行日 2018-11
著者版フラグ
値 author
戻る
0
views
See details
Views

Versions

Ver.1 2021-03-01 10:44:41.196921
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3